Lupin has signed an exclusive licence, supply and distribution agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist, strengthening its diabetes portfolio and accelerating its expansion into the obesity treatment segment.
Biopharmaceutical Innovation | 30/12/2025 | By News Bureau
Sanofi and Novartis have separately entered into agreements with the US government to reduce medicine prices for American patients while reinforcing long-term commitments to US-based manufacturing, research and innovation, marking a coordinated push to balance affordability with sustained pharmaceutical investment.
Biopharmaceutical Innovation | 22/12/2025 | By News Bureau | 170
Pfizer signs Agreement with US Government to Lower Drug Costs for American Patients
Pfizer has voluntarily agreed to implement measures designed to ensure Americans receive comparable drug prices to those available in other developed countries and pricing newly launched medicines at parity with other key developed markets.
Biopharmaceutical Innovation | 01/10/2025 | By Dineshwori | 151
Eli Lilly has voiced opposition to proposed tariffs on pharmaceutical products, cautioning that such measures could increase costs, limit patient access, and weaken US leadership in biopharmaceutical innovation.
Biopharmaceutical Innovation | 16/08/2025 | By Dineshwori | 199
VectorBuilder Signs Deal with Sartorius to Advance Biopharmaceutical Innovation
The collaboration will focus on gene vector and mRNA bioprocess solutions and services, accelerating the development and clinical translation of innovative biopharmaceutical projects.
Biopharmaceutical Innovation | 29/11/2024 | By Aishwarya | 287
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy